http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6696276-B2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_78941ed5a01bfbcd48376e1fdb485b19 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6851 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1045 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate | 2003-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2004-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eac60678f48bfe5762f45b6525691d97 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e401fa47fc5edf7a8b93ddf21490451c |
publicationDate | 2004-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-6696276-B2 |
titleOfInvention | Vasopermeability-enhancing conjugates |
abstract | Liposomal conjugates having a clinically useful delivery vehicle linked to a biologically active species which acts to increase vascular permeability and expand blood volume at or in proximity to the tumor site are disclosed. The vehicle-linked species may be, for example, a vasoactive agent, a substance that recruits or amplifies a vasoactive species, a drug, or a pharmaceutical compound. Suitable biological species comprises peptides, lipids, carbohydrates, or their derivatives. Chemical or recombinant DNA methods suitable for linking the species to the vehicles are indicated. A therapy is disclosed which comprises administering the vasoactive conjugate and delivering a diagnostic agent or a therapeutic agent at an optimal time thereafter, when tumor vasculature is maximally affected. |
priorityDate | 1988-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 344.